Molecular modes of action of artesunate in tumor cell lines

Molecular Pharmacology

Volumn 64, Issue 2, 2003, Pages 382-394

  Efferth, Thomas ^a   Sauerbrey, Axel ^b   Olbrich, Armin ^c   Gebhart, Erich ^d   Rauch, Pia ^d   Weber, H Oliver ^d,k   Hengstler, Jan G ^e   Halatsch, Marc Eric ^f   Volm, Manfred ^g   Tew, Kenneth D ^h   Ross, Douglas D ⁱ   Funk, Jens Oliver ^j  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h Fox Chase Center   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j MERCK KGAA   (Germany)

^k BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ARTESUNATE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CELL CYCLE PROTEIN; CISPLATIN; COMPLEMENTARY DNA; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GLUTAMATE CYSTEINE LIGASE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN P21; PROTEIN P53; TENIPOSIDE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PHASE; CELL PROLIFERATION; CLUSTER ANALYSIS; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CELL CYCLE; CELL DIVISION; CELL LINE, TRANSFORMED; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HL-60 CELLS; HUMANS; RNA, MESSENGER; SESQUITERPENES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0042844638     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.2.382     Document Type: Article

References (44)

1. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR (1988) Feasibility of drug screening with panels ofhuman tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
2. Asawamahasakda W, Ittarat I, Pu YM, Ziffer H, and Meshnick SR (1994) Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob Agents Chemother 38:1854-1858.
3. Batty KT, Davis TM, Thu LT, Binh TQ, Anh TK, and Ilett KF (1996) Selective high-performance liquid chromatographic determination of artesunate and alpha-and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl 677:345-350.
4. Berman PA and Adams PA (1997) Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic Biol Med 22:1283-1288.
5. Blomberg I and Hoffmann I (1999) Ectopic expression of Cdc25A accelerates the G1/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol 19:6183-6194.
6. Brügger D, Herbart H, Gekeler V, Seitz G, Liu C, Klingebiel T, Orlikowsky T, Einsele H, Denzlinger C, Bader P, et al. (1999) Functional analysis of P-glycoprotein and multidrug resistance-associated protein-related multidrug resistance in AML-blasts. Leuk Res 23:467-475.
7. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (Wash DC) 282:1497-1501.
8. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
9. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, and Davey R (2002b) Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28:160-168.
10. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, and Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18:767-773.
11. Efferth T, Fabry U, and Osieka R (1997) Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11:1180-1186.
12. Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, and Huang ES (2002c) Activity of artesunate towards wild-type, recombinant GFP-expressing sensitive and ganciclovir-resistant human cytomegaloviruses. J Mol Med 80:233-242.
13. Efferth T, Olbrich A, and Bauer R (2002a) mRNA expression profiles indicating the response of tumor cells to artesunate, arteether and artemether. Biochem Pharmacol 64:617-623.
14. Efferth T, Rücker G, Falkenberg M, Manns D, Olbrich A, Fabry U, and Osieka R (1996) Apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneim-Forsch 46:196-200.
15. el Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79-87.
16. Funk JO, Waga S, Harry JB, Espling E, Stillman B, and Galloway DA (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090-2100.
17. Galaktionov K, Chen X, and Beach D (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (Lond) 382:511-517.
18. WAF1/CIP1/ SDI1. Oncogene 11:1409-1415.
19. Hien TT, Phu NH, Mai NT, Chau TT, Trang TT, Loc PP, Cuong BM, Dung NT, Vinh H, Waller DJ, et al. (1992) An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Trans R Soc Trop Med Hyg 86:584-585.
20. Hochberg Y and Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811-818.
21. Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, and Cavenee WK (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927-2935.
22. Johnstone RW, Ruefli AA, and Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164.
23. Keselman HJ, Cribbie R, and Holland B (2002) Controlling the rate of Type I error over a large set of statistical tests. Br J Math Stat Psychol 55:27-39.
24. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretingen R, Kardos G, Diddens H, and Niethammer D (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793-6799.
25. Löwenberg B, van Putten WLJ, Touw IP, Delwel R, and Santini V (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 328:614-619.
26. Martin NM (2001) DNA repair inhibition and cancer therapy. J Photochem Photobiol B Biol 63:162-170.
27. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, and Yoshida O (1995) Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55:590-596.
28. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, and Huang HJS (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086.
29. Nagane M, Levitzki A, Gazit A, Cavenee WK, and Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 like proteases. Proc Natl Acad Sci USA 95:5724-5729.
30. O'Brien M, Kruh GD, and Tew KD (2000) The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 294:480-487.
31. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
32. Ohndorf UM, Rould MA, He Q, Pabo CO, and Lippard SJ (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (Lond) 399:708-712.
33. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092.
34. Price RN (2000) Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 9:1815-1827.
35. Reiner A, Yekutieli D, and Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19:368-375.
36. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, and Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113-1118.
37. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
38. Volm M, Koomägi R, Mattern J, and Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251-257.
39. Waldman T, Kinzler KW, and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190.
40. Walker DJ, Pitsch JL, Peng MM, Robinson B, Peters W, Bhisutthibhan J, and Meshnick SR (2000) Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob Agents Chemother 44:344-347.
41. Wang Z, Wang M, Lazo JS, and Carr BI (2002) Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem 277:19470-19475.
42. Wang ZH, Ding MX, Yuan JP, Jim ML, Hao CF, Chew-Cheng SB, Ng HK, and Chew EC (1999) Expression of bcl-2 and Bax in EGFR-antisense transfected and untransfected glioblastoma cells. Anticancer Res 19:4167-4170.
43. ARF-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 21:3207-3212.
44. Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, and Bates SE (1997) Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 3:2405-2414.